ADAPTING YOUR COURT STRUCTURE

Similar documents
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

What is drug diversion?

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Opioid Use Disorder. A Telligen White Paper. Katy Brown, PharmD Clinical Pharmacy Specialist

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

Strategies to Manage The Opioid Crisis

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

CDC s Approach to Addressing the Opioid Overdose Epidemic

Opioid Use and Other Trends

Opioid Task Force Kick-Off Meeting. February 29, 2016

MAT in the Corrections Setting

Pragmatic and Creative Responses to the Opioid Crisis in Connecticut

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Treatment Approaches for Drug Addiction

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

Prepublication Requirements

DECEMBER 7, 2017 THE OPIOID EPIDEMIC & THE UNIVERSITY S RESPONSE

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

Prescription Opioids

Understanding Medication in Addiction Treatment for Drug Court Participants

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

H NDS-ONHealth. Prescription Drug Abuse. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher.

Brief History of Methadone Maintenance Treatment

Methadone Treatment. in federal prison

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS

Policy and Political Dynamics of the Opioid Addiction Crisis in the United States

Oregon Opioid Prescribing Guidelines

Child Welfare and MOMS: Building Partnerships to Improve Care

What is the strategy?

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina

New London CARES Coordinated Access, Resources, Engagement and Support

Methadone Treatment. in federal prison

INCENTIVES, Sanctions and Therapeutic Responses BEST PRACTICE STANDARDS IN A NUTSHELL HELEN HARBERTS

Chronic Pain in Women and its Relationship to Opioid Addiction

OPIOIDS IN AMERICA. A complex crisis. A comprehensive response.

ACCG Mental Health Summit

Best Practices for Successful Reentry for People with an Opioid Addiction

Oregon Opioid Overdose Prevention Initiative

Strategies for Federal Agencies

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

2/21/2018. What are Opioids?

Rule Governing the Prescribing of Opioids for Pain

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Opioid Use Disorders &Medication Treatment

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

Vivitrol Drug Court and Medication Assisted Treatment

TN Opioid Program. Erica Schlesinger, Pharm.D

A Bill Regular Session, 2015 SENATE BILL 717

OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know

From Medicaid Transformation Approved Project Toolkit, June 2017

EI Leadership April 24, 2018

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

OUTPATIENT TREATMENT WESTPORT, CONNECTICUT

Washington State s Overdose Epidemic

Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

High-Decile Prescribers: All Gain, No Pain?

4/10/2016. Legal & Policy Approaches to Reducing Opioid Poisonings. Overview. Background. Health Directors Legal Conference April 19, 2016

Harold Rogers Update Melissa McPheeters, PhD, MPH

Prescription Opioid Overdose in Oregon: A public health perspective

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Pennsylvania Prescription Drug Monitoring Program Trends,

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:

Arizona State Office of Rural Health Webinar Series

Anyone Can Become Addicted. Anyone.

Coalition Strategies Across The Continuum of Care

IDENTIFYING ANCILLARY SERVICES

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Behavior Modification and the Seriously Mentally Ill or Functionally Impaired: Special Issues to Consider

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

OPIOID CRISIS: A PERSPECTIVE. Karl J. Haake, MD

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017

Beyond Birth: A Comprehensive Recovery Center serving parenting women

Table of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004

The Opioid Misuse Crisis and Non- Pharmacological Pain Management. Collaboration with SPTAs, Divisions and Schools

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Treatment Issues: The Opiate Crisis Among Us

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Understanding the Opiate Epidemic

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians

2017 ADDICTION PROGRAM PACKAGE

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Medicare Part D Opioid Policies for 2019 Information for Patients

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

CLINICALLY SUPERVISED EXPERIENCE for the Criminal Justice Professional (PAGE 1 of 2) APPLICANT S NAME SUPERVISOR S NAME AGENCY

Transcription:

ADAPTING YOUR COURT STRUCTURE Developed by: National Drug Court Institute NDCI, March 2018 The following presentation may not be copied in whole or in part without the written permission of the author of the National Drug Court Institute. Written permission will generally be given upon request.

DEADLY OUTCOMES High risk to overdose and die Requires rapid upfront interventions Basic needs such as food and stable living must be addressed prior to other concerns Quick linkage to treatment and frequent on-going communication with treatment and case manager

DRUG USE DISORDERS: HIGH RELAPSE RATES High Probability of Relapse some say 50% after 1 st year Multifactorial Reasons for Relapse Genetic (heritable vulnerability) Environmental (exposure) Biological (demonstrated pathophysiology) Behavioral (lifestyle aspects) National Institute on Drug Abuse (NIDA) A chronic, relapsing brain disease characterized by compulsive drugseeking and use despite harmful consequences and by longlasting structural and functional changes in the brain

COURT ADAPTATION 1: TEAM

MAT: TEAM BELIEFS Have open discussion of team s perceptions False beliefs It s not real recovery It s just replacing one drug with another One medication should work for everyone Focus should be on ending medication quickly

EXPAND THE TEAM Prescriber Psychiatrist Physician Nurse Practitioner Physician Assistant Registered Nurse

HOW? Some ideas for finding prescribers: Patient s own physicians Local Federally Qualified Health Centers (FQHCs) American Society of Addiction Medicine (ASAM) membership directory and American Psychiatrist and Psychologist Association (APPA) The local American Medical Association(AMA) chapter. See if you can present at a meeting or conference, or if they will work with you to find physicians willing to provide MAT.

HOW? An high-level influential person from your Department of Public Health or state medical society. Ask this person to make an appeal to physicians on your behalf. The pharmaceutical company that developed the medication. A representative may also be able to help you recruit physicians.

EXPAND THE TEAM Identify consumer groups MARS Recovery Coaches Family Members

IDENTIFY THE NEIGHBORHOOD Law Enforcement/Probation Recreational/Libraries Mental Health Services Family Therapy Faith Community Community Foundations Schools/Colleges/Universities Government Agencies/Officials Drug Court Social Services Service Organizations Housing Arts Health Employment/Job Training Mentoring Programs Residents Transportation Literacy Programs Treatment Businesses Community-Based Organizations

TEAM TRAINING NEEDS On-line Mental health treatment Substance use treatment Trauma What else?

CHRONIC PAIN

WHAT IS CHRONIC PAIN? Most common complaint among those seeking medical care Pain lasting longer than the normal time for healing Persistent pain that is either constant or intermittent

EXAMPLE OF OPIOID PAIN RELIEVERS

EVOLUTION OF AN EPIDEMIC The Joint Commission recommendation Drug companies marketing strategy (safe, non-addictive) Stage set for increased opioid prescribing

EVOLUTION OF AN EPIDEMIC Time-release version of oxycodone, OxyContin, was introduced in 1996 Heavily marketed Chances of addiction were touted as miniscule because of the timerelease formulation

CONSEQUENCES Alarming increases in negative consequences related to their abuse. Emergency department visits increased from 144,600 in 2004 to 305,900 in 2008 Treatment admissions for primary misuse of opioids other than heroin increased from 1% of all admissions in 1997 to 5% in 2007 Overdose deaths due to prescription opioid pain relievers more than tripled in the past 20 years

REACTIONS New more tamper proof drug formulations Restrictions on doctor prescribing Efforts to stop online sales On June 16, 2016 delegates testified at the AMA s annual meeting that pain should be removed as a "fifth vital sign."

PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPS)

PRESCRIPTION DRUG MONITORING PROGRAMS Collect electronically transmitted Rx data From prescribers & dispensers (i.e., pharmacies) Allow prescribers and dispensers to check their active patients Rx history Instituted in DC and all states but Missouri A few states mandate participation Medicaid officials may have access but private health plan case managers, pharmacy managers, fraud control, & Medical Review Officers currently do not

USES FOR PRESCRIPTION DRUG MONITORING PROGRAMS Prevention Early intervention Surveillance Education

YOUR EXPERIENCE How many of your clients report being prescribed opioid medications for chronic pain?

WHY OPIOIDS AREN T A GOOD CHOICE TO TREAT CHRONIC PAIN Overdose Risk Risk of addiction Tolerance Withdrawal Cognitive impairment Reduced coordination Brain (neuronal) changes Constipation Low testosterone Impaired healing Obstructive sleep apnea Hyperalgesia

PRENATAL EXPOSURE TO OPIOIDS HAS PREGNANCY IMPACTS An increasing percentage of women of childbearing age are using opioids Increased risks for stillbirth, prematurity, birth defects Medication Assisted Therapy (MAT) cannot be stopped during pregnancy Neonatal Abstinence Syndrome is on the rise Opioid withdrawal symptoms for newborn on delivery Withdrawal treatment of newborn is tapered & stopped over several days or weeks as symptoms subside

HELPING YOUR CLIENTS NAVIGATE WITH THE PROVIDER

BEST APPROACHES FOR DEALING WITH CHRONIC PAIN AMONG OPIOID USERS Step 1: Begins with a discussion on the causes of pain, non-narcotic medications, and advice on how to resume normal activities Step 2: self-management techniques, meditation, tai chi, yoga, exercise, injections, therapeutic massage, acupuncture, physical therapy, and spinal manipulation

BEST APPROACHES FOR DEALING WITH CHRONIC PAIN AMONG OPIOID USERS Step 3: Targets patients who need even more intensive interventions before they can return to normal activities in work and family life. The intensive interventions are often coordinated by interdisciplinary pain center-based teams and may rely on opioids

SUMMARY: OPIOIDS AND PAIN Opiate abuse is a huge national problem, but so is chronic pain. There are many effective ways to treat chronic pain that don t involve opioids If opiates are used there are safe ways to use them and monitor patients to keep them safer. For those who have developed addiction, treatment can be effective

PAW has Fact Sheets on Much of This Material http://publichealth.hsc.wvu.edu/icrc/prevention-of-prescription-drug-abuse-in-the-workplace/samhsafact-sheets/ or search wvu SAMHSA fact sheets

COURT ADAPTATION 2: PROCESS

COURT HEARINGS AND JUDICIAL MONITORING More frequent court hearings may be needed Hearings provide a good opportunity to recognize and reward positive behavioral change Language is important! Treat like any other treatment show no bias.

COURT ADAPTATION 3: TREATMENT

TREATMENT Table Exercise with the RFP

CASE MANAGEMENT Intensive Smaller caseloads Identify existing services Reduce conflicts between providers Assist the client (consumer) Consistent messaging about recovery

SAMPLE WEEKLY SHEET

PREPARING CLIENTS FOR MEDS Encourage clients to: Express concerns Ask questions Take notes Take as prescribed Open to medication prescribed

WORKING WITH THE FAMILY Counseling Community support Engage Non-traditional Narcan training

COURT ADAPTATION 4: SUPERVISION

COMMUNITY SUPERVISION CHALLENGES Smaller and specialized caseloads Case plans developed based on a validated assessment- time specific identifying problem, goals and strategies. More frequent home visits as often times these clients move frequently, have criminal associates that are present

COMMUNITY SUPERVISION CHALLENGES Medication Monitoring- Often times clients are prescribed medications that are addictive or mood altering. They also are hopefully receiving MAT as determined by a Physician We must be diligent in monitoring the medications. DEA data base/ Medication Letter/ Pill counting

EXAMPLE DOCTOR LETTER Your patient is currently on supervised probation and in the Drug Court Program. They have been diagnosed with a Substance Use Disorder and are currently in Substance Abuse Treatment. As part of the Drug Court program, your patient must provide documentation to the Probation Department within 72 hours if they are prescribed any pain medication, muscle relaxants, stimulants, anxiety medications or any other mood altering medication. As you know, all of these medications can be harmful to the treatment and recovery of Substance Use Disorders. If at all possible we would ask they be given an alternative medication, but we know this is not possible in all cases. In an effort to support the client in the recovery process we require frequent drug testing and monitor the DEA database to ensure the client is not seeking medication from multiple physicians. Unless the following documentation is faxed to us, any positives drug test will result in a sanction for the client up to and including incarceration. Therefore we would ask that you please Fax the following information to:

EXAMPLE DOCTOR LETTER Patient Name: Date of Service: Diagnosis & Code(s): Medication(s) prescribed: Dosage(s) Prognosis & length of treatment Name and address of agency Phone number FAX Number: Physician Name (please print) DEA #: Physician signature Date:

COMMUNITY SUPERVISION CHALLENGES Fugitive warrant receive priority Significant upfront supervision and then taper off as they become more stable and are meeting case plan goals Update case plans to ensure participant is achieving progress towards decreased likelihood of reoffending

ADJUST EXPECTATIONS Lifelong engagement in treatment is necessary and desirable. Highly structured program Titration is not appropriate unless the doctors discuss with the clients

PHASE ADJUSTMENTS Proximal Goals Distal Goals

FLEXIBLE INCENTIVES AND SANCTIONS No zero tolerance Wide range of rewards/incentives Considerations: Housing Medications Treatment participation

Considerations in Responding to Participant Behavior 1) WHO are they in terms of risk and need? 2) WHERE are they in the program (i.e., what phase)? 3) WHICH behaviors are we responding to (i.e., are they proximal or distal)? 4) WHAT is the response choice magnitude? 5) HOW to deliver and explain the response?